News for Bio-Techne Corporation (TECH)

TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.

PR NewswireMINNEAPOLIS, March 24, 2025 MINNEAPOLIS, March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancemen

PR NewswireMINNEAPOLIS, March 10, 2025 MINNEAPOLIS, March 10, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun

PR NewswireMINNEAPOLIS and OXFORD, England, March 3, 2025 AmplideX® Nanopore Carrier Plus Kit uses nanopore sequencing to resolve high-prevalence genes. M

Weitz Investment Management, an investment management firm, released its “Partners III Opportunity Fund” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here.

Discover Bio-Techne's strong growth in Protein Sciences & Spatial Biology despite market pressure. Explore more details here.

PR NewswireMINNEAPOLIS, Feb. 27, 2025 MINNEAPOLIS, Feb. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present

TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

PR NewswireMINNEAPOLIS, Feb. 18, 2025 MINNEAPOLIS, Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative li

Earnings Call Insights: Bio-Techne Corporation (NASDAQ:TECH) Q2 2025Management ViewCEO Kim Kelderman highlighted 9% organic revenue growth for the quarter,...

Bio-Techne Corporation (NASDAQ:TECH) Q2 2025 Earnings Conference Call February 5, 2025 9:00 AM ETCompany ParticipantsDavid Clair - Vice President-Investor...

TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.

Bio-Techne Corporation (TECH) stock climbs as its Q2 FY25 results exceed Wall Street estimates amid recovery in the biopharma end market. Read more here.

Bio-Techne (TECH) maintains $0.08/share quarterly dividend, with a forward yield of 0.44%. Dividend payable Feb. 28 for shareholders of record Feb.

Bio-Techne Corp (TECH), in collaboration with ScaleReady, Wilson Wolf Manufacturing, and CellReady, announced on January 21, 2025, that BrainChild Bio has been

PR NewswireMINNEAPOLIS, Jan. 21, 2025 MINNEAPOLIS, Jan. 21, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will

PR NewswireMINNEAPOLIS, Jan. 7, 2025 MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a

TECH enters a co-marketing and co-promotion agreement with Waters Corporation to expand the reach of advanced biotherapeutic characterization and development processes.